[go: up one dir, main page]

ATE279433T1 - Cystein-protease-inhibitoren für die behandlung von allergischenkrankheiten verursacht durch ige - Google Patents

Cystein-protease-inhibitoren für die behandlung von allergischenkrankheiten verursacht durch ige

Info

Publication number
ATE279433T1
ATE279433T1 AT96924976T AT96924976T ATE279433T1 AT E279433 T1 ATE279433 T1 AT E279433T1 AT 96924976 T AT96924976 T AT 96924976T AT 96924976 T AT96924976 T AT 96924976T AT E279433 T1 ATE279433 T1 AT E279433T1
Authority
AT
Austria
Prior art keywords
compounds
allergens
pct
treatment
allergic diseases
Prior art date
Application number
AT96924976T
Other languages
English (en)
Inventor
Tony Johnson
Terrance Hart
Peter Laing
Farouk Shakib
Martin Quibell
Original Assignee
Medivir Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9514616.3A external-priority patent/GB9514616D0/en
Priority claimed from GBGB9522221.2A external-priority patent/GB9522221D0/en
Application filed by Medivir Uk Ltd filed Critical Medivir Uk Ltd
Application granted granted Critical
Publication of ATE279433T1 publication Critical patent/ATE279433T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT96924976T 1995-07-17 1996-07-17 Cystein-protease-inhibitoren für die behandlung von allergischenkrankheiten verursacht durch ige ATE279433T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9514616.3A GB9514616D0 (en) 1995-07-17 1995-07-17 Cleavage of low affinity receptor for human IgE
GBGB9522221.2A GB9522221D0 (en) 1995-10-31 1995-10-31 Compounds for use in treatment of ige mediated allergic diseases
PCT/GB1996/001707 WO1997004004A1 (en) 1995-07-17 1996-07-17 CYSTEINE PROTEASE INHIBITORS FOR USE IN TREATMENT OF IgE MEDIATED ALLERGIC DISEASES

Publications (1)

Publication Number Publication Date
ATE279433T1 true ATE279433T1 (de) 2004-10-15

Family

ID=26307419

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96924976T ATE279433T1 (de) 1995-07-17 1996-07-17 Cystein-protease-inhibitoren für die behandlung von allergischenkrankheiten verursacht durch ige

Country Status (9)

Country Link
US (1) US6034066A (de)
EP (1) EP0839155B1 (de)
JP (1) JPH11509543A (de)
AT (1) ATE279433T1 (de)
AU (1) AU716716B2 (de)
CA (1) CA2227198A1 (de)
DE (1) DE69633623T2 (de)
ES (1) ES2230566T3 (de)
WO (1) WO1997004004A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020331A (en) * 1995-03-24 2000-02-01 Molecumetics, Ltd. β-sheet mimetics and use thereof as protease inhibitors
US6699869B1 (en) * 1995-03-24 2004-03-02 Myriad Genetics Inc. β-sheet mimetics and use thereof as inhibitors of biologically active peptides or proteins
PL330814A1 (en) 1996-06-20 1999-06-07 Regents Board Of Compounds for and methods of delivering pharmaceutical preparations and their application
GB9726114D0 (en) * 1997-12-11 1998-02-11 Univ Manchester Prevention and/or treatment of allergic conditions
CA2225325A1 (en) * 1997-12-19 1999-06-19 The University Of British Columbia Hemiasterlin analogs
US6913749B2 (en) * 1998-11-02 2005-07-05 Resistentia Pharmaceuticals Ab Immunogenic polypeptides for inducing anti-self IgE responses
US7759133B2 (en) * 1998-12-22 2010-07-20 Alk-Abello A/S Method of detecting and/or quantifying a specific IgE antibody in a liquid sample
US6649593B1 (en) * 1999-10-13 2003-11-18 Tularik Inc. Modulators of SREBP processing
US6849260B2 (en) 2000-08-18 2005-02-01 Amgen Inc. Methods and compositions for treating IgE-related disease using NNT-1 inhibitors
US20070196353A1 (en) * 2001-05-25 2007-08-23 Hugh Payton Method for reducing allergenicity in indoor spaces
US20020176854A1 (en) * 2001-05-25 2002-11-28 Payton Hugh W. Method for reducing allergenicity in indoor spaces
CN1642550A (zh) * 2002-02-14 2005-07-20 美瑞德生物工程公司 β－折叠模拟物和组合物及其有关方法
US20040007251A1 (en) * 2002-07-10 2004-01-15 Kimberly-Clark Worldwide, Inc. Cleaners for the control and removal of allergens
US7037535B2 (en) * 2002-11-19 2006-05-02 Kimberly-Clark Worldwide, Inc. Method and composition for neutralizing house dust mite feces
US7211407B2 (en) * 2003-07-15 2007-05-01 Chan Test, Inc. High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
WO2006099261A2 (en) * 2005-03-11 2006-09-21 The University Of North Carolina At Chapel Hill Potent and specific immunoproteasome inhibitors
US20080118524A1 (en) * 2006-10-20 2008-05-22 Stefan Persson Anti-IgE Vaccines
US20100279996A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Novel analgesic that binds filamin a
US20100279997A1 (en) 2009-05-04 2010-11-04 Lindsay Burns Barbier Analgesic that binds filamin a
GB201001070D0 (en) 2010-01-22 2010-03-10 St George's Hospital Medical School Theraputic compounds and their use
GB201011411D0 (en) * 2010-07-06 2010-08-18 St Georges Hosp Medical School Therapeutic compounds and their use
US9433604B2 (en) 2013-10-08 2016-09-06 Pain Therapeutics Inc. Method for inhibiting growth of cancer cells

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH603513A5 (de) * 1975-02-05 1978-08-15 Sandoz Ag
JPH04273897A (ja) * 1991-02-27 1992-09-30 Taisho Pharmaceut Co Ltd トリペプチド誘導体
JPH04273896A (ja) * 1991-02-27 1992-09-30 Taisho Pharmaceut Co Ltd トリペプチド誘導体
JPH05213990A (ja) * 1991-02-27 1993-08-24 Taisho Pharmaceut Co Ltd トリペプチド誘導体
US5714484A (en) * 1993-12-08 1998-02-03 Prototek, Inc. α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors
US5486623A (en) * 1993-12-08 1996-01-23 Prototek, Inc. Cysteine protease inhibitors containing heterocyclic leaving groups
EP0731693A1 (de) * 1993-12-08 1996-09-18 Vitaphore Corporation Mikrophaere enthaltendes system zur wirkstoffabgabe

Also Published As

Publication number Publication date
DE69633623D1 (de) 2004-11-18
WO1997004004A1 (en) 1997-02-06
AU6524296A (en) 1997-02-18
JPH11509543A (ja) 1999-08-24
CA2227198A1 (en) 1997-02-06
EP0839155B1 (de) 2004-10-13
ES2230566T3 (es) 2005-05-01
EP0839155A1 (de) 1998-05-06
DE69633623T2 (de) 2005-12-01
AU716716B2 (en) 2000-03-02
US6034066A (en) 2000-03-07

Similar Documents

Publication Publication Date Title
DE69633623D1 (de) CYSTEIN-PROTEASE-INHIBITOREN FÜR DIE BEHANDLUNG VON ALLERGISCHENKRANKHEITEN VERURSACHT DURCH IgE
ATE443043T1 (de) Phenylcarboxamide als beta-sekretase-hemmer zur behandlung von alzheimer
DE69404039D1 (de) Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
ATE451369T1 (de) Piperidinopyrimidindipeptidylpeptidaseinhibitor n zur behandlung von diabetes
PT799209E (pt) Novas sulfonamidas
DE60137329D1 (de) Zusammensetzungen zur behandlung von diabetes die einen dp iv-inhibitoren und einen andere antidiabetikum enthalten
ECSP045115A (es) INDOL-2-CARBOXAMIDAS COMO INHIBIDORES DEL FACTOR Xa
DE69330403D1 (de) Behandlung und prophylaxe von durch parasiten oder bakterien verursachten erkrankungen
DE69533264D1 (de) Inhibitoren der il-6 aktivitaet
ATE416761T1 (de) Prävention und behandlung von durch entzündung ausgelöstem und/oder immunvermitteltem knochenschwund
ATE204164T1 (de) Pflaster zur behandlung von nagelmykosen
ATE447574T1 (de) 3-amino-4-phenylbutansäurederivate als dipeptidylpeptidase-hemmer zur behandlung oder vorbeugung von diabetes
HUP0102550A2 (hu) IgE választ befolyásoló tulajdonságú vegyületek
DE60226729D1 (de) Hydroxyalkylaminderivate als beta-secretase-inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE297755T1 (de) Verwendung von lactoferrin in der behandlung von beschwerden, die von allergenen verursacht sind
ATE171873T1 (de) Antiglucocorticoidsteroide zur behandlung von angststörungen
ATE177646T1 (de) Protein präparate zur verhütung und behandlung van periodontitis und sonstigen bakteriellen erkrankungen der mundhöhle
NO20054744L (no) Behandling av Alzheimers sykdom
DE69418035D1 (de) Hiv-proteaseinhibitoren
ATE190843T1 (de) Zubereitungen zur behandlung von impotenz, die ein alpha-1 inhibitor und ein alpha-2 inhibitor enthalten
DK0652900T3 (da) Thrombininhibitorer
FR2842422B1 (fr) Compositions destinees au traitement des neuropathies peripheriques, preparation et utilisations
ATE273708T1 (de) Wirkstoff zur prophylaxis und behandlung von krankheiten durch thromboxane a2 vermittelt
DE50203154D1 (de) Benzimidazolderivate zur behandlung von mit mikroglia-aktivierung assoziierten erkrankungen wie inflammatorische, allergische, infektiöse oder autoimmune erkrankungen
DE50302552D1 (de) Verwendung von treosulfan und derivaten davon zur behandlung der multiplen sklerose

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties